Acute lymphoblastic leukemia (ALL) is a heterogeneous disease at the genetic level.
Chromosomal abnormalities are used as diagnostic, prognostic and predictive biomarkers to …

Transcription factor IKZF1 (IKAROS) acts as a critical regulator of lymphoid differentiation
and is frequently deleted or mutated in B-cell precursor acute lymphoblastic leukemia. IKZF1 …

Genomic studies of pediatric cancer have primarily focused on specific tumor types or high-
risk disease. Here, we used a three-platform sequencing approach, including whole …

Acute lymphoblastic leukaemia (ALL) occurs at all ages but is the most common cancer of
childhood. The current treatment of paediatric ALL is highly successful with up to 90 …

Chromosomal abnormalities are increasingly used to risk stratify adults with acute
lymphoblastic leukemia. Published data describing the age-specific incidence of …

Rapid advances in genomics have opened unprecedented possibilities to explore the
mutational landscapes in malignant diseases, such as B-cell acute lymphoblastic leukemia …

Abstract High hyperdiploidy (51–67 chromosomes) is the most common cytogenetic
abnormality pattern in childhood B‐cell precursor acute lymphoblastic leukemia (ALL) …

B-lymphocyte development in the bone marrow is controlled by the coordinated action of
transcription factors creating regulatory networks ensuring activation of the B-lymphoid …

TET2 is a dioxygenase that catalyses multiple steps of 5-methylcytosine oxidation. Although
TET2 mutations frequently occur in various types of haematological malignancies, the …

Traditional treatment regimens for adult acute lymphoblastic leukemia, including allogeneic
hematopoietic cell transplantation, result in an overall survival of approximately 40%, a …